Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis

Background: Infliximab (IFX) and vedolizumab (VDZ), frequently used biologics in inflammatory bowel disease (IBD), are available as intravenous (IV) and subcutaneous (SC) formulations; however, comparative data are limited. Objectives: To compare the rates of discontinuation due to lack of efficacy...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Marc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Jean-Frédéric Colombel, Silvio Danese, Roberto Faggiani, Jordi Guardiola, Stephen B. Hanauer, Jorgen Jahnsen, Walter Reinisch, Xavier Roblin, Philip J. Smith, Taek Sang Kwon, Seungmin Kim, Kyoungwan Nam, Raja Atreya
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SAGE Publishing 2025-10-01
Edice:	Therapeutic Advances in Gastroenterology
On-line přístup:	https://doi.org/10.1177/17562848251383767
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!